Merck Announces New Data from KEYNOTE-028 Trial Evaluating KEYTRUDA Across Range of Cancer Types, Presented at 2015 ECC

Merck

, known as MSD outside the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to Merck's growing body of clinical data for KEYTRUDA. KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket trial – a trial design that allows for the study of multiple sub-populations of different tumor or histological types within